{"DataElement":{"publicId":"7125052","version":"1","preferredName":"Tumor Segment Percent Necrotic Surface Area Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.","longName":"7120646v1.0:6847952v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7120646","version":"1","preferredName":"Tumor Segment Percent Necrotic Surface Area","preferredDefinition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis._A quantitative measurement of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.","longName":"7119487v1.0:7120644v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7119487","version":"1","preferredName":"Tumor Segment","preferredDefinition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","longName":"C162622","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Segment","conceptCode":"C162622","definition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7C823A-3A71-01FE-E053-F662850AC3D6","latestVersionIndicator":"Yes","beginDate":"2020-01-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-06","modifiedBy":"ONEDATA","dateModified":"2020-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7120644","version":"1","preferredName":"Percent Necrotic Surface Area","preferredDefinition":"A quantitative measurement of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.\r\n\r\n","longName":"C165618","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percent Necrotic Surface Area","conceptCode":"C165618","definition":"A quantitative measurement of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7CF101-6094-020A-E053-F662850AF630","latestVersionIndicator":"Yes","beginDate":"2020-01-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-06","modifiedBy":"ONEDATA","dateModified":"2020-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435029","version":"1","preferredName":"Molecular Abnormality","preferredDefinition":"Abnormalities that occur in human cells and tissues and models of human cancer.","longName":"C3910","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07432BB3-787B-25DB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B7CF101-60A5-020A-E053-F662850AF630","latestVersionIndicator":"Yes","beginDate":"2020-01-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeDescription":"1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/6/20 jk created for CPTAC Path Review CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6847952","version":"1","preferredName":"Integer","preferredDefinition":"A positive number with no fractional part between 0 and 100.","longName":"6847952v1.0","context":"OCCPR","contextVersion":"1","type":"Non-enumerated","dataType":"Integer","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433737","version":"1","preferredName":"Integer","preferredDefinition":"A number with no fractional part.","longName":"C45255","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4769-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-25","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-25","modifiedBy":"ONEDATA","dateModified":"2005-11-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F867DFE-8763-5C6C-E053-F662850A9F8B","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-01-22","changeDescription":"1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set.  8/7/19 jk created for CPTAC baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7639000","version":"1","longName":"CM Pathology Review","context":"OCCPR"},{"publicId":"5635361","version":"1","longName":"Bladder","context":"OCCPR"},{"publicId":"6779607","version":"1","longName":"BLCA Local Pathology","context":"OCCPR"},{"publicId":"6779608","version":"1","longName":"BLCA Pathology Review","context":"OCCPR"},{"publicId":"6570064","version":"1","longName":"Stomach","context":"OCCPR"},{"publicId":"6779567","version":"1","longName":"STAD Local Pathology","context":"OCCPR"},{"publicId":"6779568","version":"1","longName":"STAD Pathology Review","context":"OCCPR"},{"publicId":"10000439","version":"1","longName":"Thyroid","context":"OCCPR"},{"publicId":"6779572","version":"1","longName":"THCA Local Pathology","context":"OCCPR"},{"publicId":"6779573","version":"1","longName":"THCA Pathology Review","context":"OCCPR"},{"publicId":"6776735","version":"1","longName":"Eye","context":"OCCPR"},{"publicId":"6779575","version":"1","longName":"UVM Local Pathology","context":"OCCPR"},{"publicId":"6779576","version":"1","longName":"UVM Pathology Review","context":"OCCPR"},{"publicId":"6570063","version":"1","longName":"Cervix","context":"OCCPR"},{"publicId":"6779610","version":"1","longName":"CESC Local Pathology","context":"OCCPR"},{"publicId":"6779611","version":"1","longName":"CESC Pathology Review","context":"OCCPR"},{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779539","version":"1","longName":"CHOL Local Pathology","context":"OCCPR"},{"publicId":"6779540","version":"1","longName":"CHOL Pathology Review","context":"OCCPR"},{"publicId":"6779542","version":"1","longName":"LIHC Local Pathology","context":"OCCPR"},{"publicId":"6779543","version":"1","longName":"LIHC Pathology Review","context":"OCCPR"},{"publicId":"6601282","version":"1","longName":"Esophagus","context":"OCCPR"},{"publicId":"6779554","version":"1","longName":"ESCA Local Pathology","context":"OCCPR"},{"publicId":"6779555","version":"1","longName":"ESCA Pathology Review","context":"OCCPR"},{"publicId":"5635376","version":"1","longName":"Prostate","context":"OCCPR"},{"publicId":"6779562","version":"1","longName":"PRAD Local Pathology","context":"OCCPR"},{"publicId":"6779563","version":"1","longName":"PRAD Pathology Review","context":"OCCPR"},{"publicId":"6601275","version":"1","longName":"Brain","context":"OCCPR"},{"publicId":"6779545","version":"1","longName":"LGG Local Pathology","context":"OCCPR"},{"publicId":"6779546","version":"1","longName":"LGG Pathology Review","context":"OCCPR"},{"publicId":"7218867","version":"1","longName":"Head and Neck","context":"OCCPR"},{"publicId":"7634287","version":"1","longName":"HNSCC Pathology Review","context":"OCCPR"},{"publicId":"7638999","version":"1","longName":"HNSCC Local Pathology","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Percent of the surface area o","type":"Preferred Question Text","description":"Percent of the surface area of the tissue section that is necrotic","url":null,"context":"OCCPR"},{"name":"CPTAC-1","type":"Coding Instructions","description":"The percent of the surface area of the tissue section that is necrotic is represented as the area of necrosis (numerator) as compared to the area of the entire tissue section (denominator).","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA3DB66-F99A-7701-E053-F662850A4E71","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"COLBERTM","dateModified":"2022-09-11","changeDescription":"8/17/21 jk added CM Path Rpt CSI. 7/12/21 jk added HNSCC Path Rpt CSI. 4/30/20 jk added CPTAC LGG Path CSI.  1/29/20 jk added coding instruction from Linda.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review and Local Path CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}